Related Experiment Video

Updated: Jan 13, 2026

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
08:00

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

6.5K

Targeting Inflammation: Cytosporone B Modulates Imatinib-Driven Biochemical Alterations in Rat Heart

Denise Börzsei1, András Nagy1, Viktória Kiss1

  • 1Department of Physiology, Anatomy, and Neuroscience, Faculty of Science and Informatics, University of Szeged, H-6726 Szeged, Hungary.

International Journal of Molecular Sciences
|October 29, 2025
PubMed

Insights

Cytosporone B (CsnB) may protect the heart from Imatinib chemotherapy side effects. CsnB treatment reduced key inflammatory and oxidative markers in rat hearts exposed to Imatinib.

Area of Science:

  • Cardiovascular Pharmacology
  • Natural Product Chemistry
  • Oncology Supportive Care

Background:

  • Chemotherapy improves cancer survival but causes cardiotoxicity.
  • Natural compounds are explored to mitigate chemotherapy adverse effects.
  • Imatinib is a chemotherapy agent with known cardiovascular risks.

Purpose of the Study:

  • To investigate Cytosporone B (CsnB) as a cardioprotective agent against Imatinib-induced cardiotoxicity.
  • To evaluate CsnB's ability to counteract cardiac inflammation and oxidative stress caused by Imatinib.

Main Methods:

  • Male Wistar rats were divided into control, Imatinib-treated, and Imatinib + CsnB-treated groups.
  • Rats received daily oral Imatinib (60 mg/kg) and/or intraperitoneal CsnB (5 mg/kg) for two weeks.
  • Cardiac tissues were analyzed for markers of inflammation (HMGB1, TNF-α, MPO, iNOS, PAD4) and oxidative stress (NOX4).

Main Results:

  • Imatinib treatment significantly upregulated cardiac HMGB1, TNF-α, MPO, iNOS, PAD4, and NOX4.
  • CsnB co-treatment markedly mitigated these Imatinib-induced elevations in inflammatory and oxidative markers.
  • CsnB demonstrated a significant role in opposing Imatinib-induced cardiac damage.

Conclusions:

  • Cytosporone B (CsnB) shows potential as a cardioprotective agent against Imatinib-induced cardiotoxicity.
  • CsnB effectively modulates inflammatory and oxidative pathways implicated in Imatinib's adverse cardiac effects.
  • Further research is warranted to explore CsnB's therapeutic application in cancer patients undergoing chemotherapy.
Keywords:
Cytosporone BImatinibheartinflammation

More Related Videos

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

418
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

2.5K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K